Webinar, topic: "Biosimilars and the BPCI Act: Where Are We Now and Where Are We Going?"
Kenneth Burchfiel and Dr. William J. Simmons featured as panelists on an upcoming American Bar Association webinar. (CLE credit available)
Kenneth Burchfiel and Dr. William J. Simmons are members of the biosimilar practice group at Sughrue Mion, PLLC which addresses the complex patent issues associated with the BPCI. Sughrue has been at the forefront of this law and provides strategic counseling regarding all aspects of the intellectual property issues raised by the Approval Pathway for Biosimilar Biological Products. The intricate US Pathway sets forth the law for the production, use and sale of follow-on biologic therapeutics in the U.S., including provisions designed for determining the outcome of intellectual property disputes. During this webinar, Kenneth Burchfiel and Dr. William J. Simmons will discuss some of the critical patent issues involved in exploitation of the BPCI, in view of the America Invents Act (AIA).